The Proportions and Rates of Economic Activities as a Factor of Gross Value Added Maximization in Transition Economy
Scientific Annals of Economics and Business · 2016
DOI: 10.1515/saeb-2016-0104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Annals of Economics and Business, 2016. Verfasst von Yaroslav I. Vyklyuk und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sustain growth of value added is one of the most important problem in many countries with transition economy. The article provides new evidence about determining the future dynamics of the economic activities with increasing value added. In this paper, we have used Hopfield’s neural network to clarify the strategies of social and economic development of country. Three types of strategies have been created with using mathematical models and quantitative assessment of their efficiency has been made. From the simulation results, it is observed that state regulation based on this methodology can build the basis for further improvements in economic policy.
Zitieren
APA
Vyklyuk, Y. I., Yevdokymenko, V. K., & Yaskal, I. V. (2016). The Proportions and Rates of Economic Activities as a Factor of Gross Value Added Maximization in Transition Economy. Scientific Annals of Economics and Business. https://doi.org/10.1515/saeb-2016-0104
Vancouver
Vyklyuk YI, Yevdokymenko VK, Yaskal IV. The Proportions and Rates of Economic Activities as a Factor of Gross Value Added Maximization in Transition Economy. Scientific Annals of Economics and Business. 2016. doi:10.1515/saeb-2016-0104
BibTeX
@article{Vyklyuk2016,
author = {Vyklyuk, Yaroslav I. and Yevdokymenko, Valeriy K. and Yaskal, Ihor V.},
title = {The Proportions and Rates of Economic Activities as a Factor of Gross Value Added Maximization in Transition Economy},
journal = {Scientific Annals of Economics and Business},
year = {2016},
doi = {10.1515/saeb-2016-0104}
}
EUVIMED